Plasma DNA methylation: A potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease

Gut

Volumn 66, Issue 7, 2017, Pages 1321-1328

  Hardy, Timothy ^a,b   Zeybel, Mujdat ^c   Day, Christopher P ^a   Dipper, Christian ^b   Masson, Steven ^b   McPherson, Stuart ^b   Henderson, Elsbeth ^b   Tiniakos, Dina ^a,b   White, Steve ^b   French, Jeremy ^b   Mann, Derek A ^a   Anstee, Quentin M ^a,b   Mann, Jelena ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c KOÇ UNIVERSITY   (Turkey)

Author keywords

HEPATIC FIBROSIS; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NONALCOHOLIC STEATOHEPATITIS; PPAR GAMMA

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GENETIC MARKER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ALCOHOL LIVER DISEASE; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DNA METHYLATION; EPIGENETIC REPRESSION; FEMALE; HEPATIC STELLATE CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LIVER BIOPSY; LIVER FIBROSIS; MALE; MYOFIBROBLAST; NEXT GENERATION SEQUENCING; NONALCOHOLIC FATTY LIVER; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; CASE CONTROL STUDY; GENETIC MARKER; GENETICS; HIGH THROUGHPUT SEQUENCING; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; GENETIC MARKERS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PPAR GAMMA; SEVERITY OF ILLNESS INDEX;

EID: 84962873354     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-311526     Document Type: Article

References (35)

1. Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:645-55.
2. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-44.
3. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
4. McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol 2015;62:1148-55.
5. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.e9.
6. Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013;59:550-6.
7. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54.
8. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-97.e10.
9. Baumeister SE, Völzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008;134:85-94.
10. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265-9.
11. Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013;66:1033-45.
12. Cassinotto C, Boursier J, De Ledinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of Supersonic Shear Imaging, FibroScan and ARFI with liver biopsy. Hepatology Published Online First: 22 Jan 2016. doi:10.1002/hep. 28394
13. Mann DA. Epigenetics in liver disease. Hepatology 2014;60:1418-25.
14. Illingworth RS, Bird AP. CpG islands-'a rough guide'. FEBS Lett 2009;583:1713-20.
15. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
16. Page A, Paoli P, Salvador EM, et al. Hepatic stellate cell transdifferentiation involves genome-wide remodeling of the DNA methylation landscape. J Hepatol 2016;64:661-73.
17. Booth MJ, Branco MR, Ficz G, et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 2012;336:934-7.
18. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41:178-86.
19. Mann J, Chu DC, Maxwell A, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010;138:705-14, 14.e1-4.
20. Mann J, Oakley F, Akiboye F, et al. Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ 2007;14:275-85.
21. Zeybel M, Hardy T, Wong YK, et al. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med 2012;18:1369-77.
22. Zeybel M, Hardy T, Robinson SM, et al. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics 2015;7:25.
23. Barak Y, Kim S. Genetic manipulations of PPARs: effects on obesity and metabolic disease. PPAR Res 2007;2007:12781.
24. Chawla A, Repa JJ, Evans RM, et al. Nuclear receptors and lipid physiology: opening the X-files. Science 2001;294:1866-70.
25. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-4.
26. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54.
27. DE Kleiner, EM Brunt, M Van Natta, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
28. Sun K, Jiang P, Chan KC, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci USA 2015;112:E5503-12.
29. Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000;275:35715-22.
30. Hazra S, Xiong S, Wang J, et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 2004;279:11392-401.
31. Morán-Salvador E, Titos E, Rius B, et al. Cell-specific PPARgamma deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. J Hepatol 2013;59:1045-53.
32. Nevzorova YA, Hu W, Cubero FJ, et al. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Biochim Biophys Acta 2013;1832:1765-75.
33. Gazit V, Huang J, Weymann A, et al. Analysis of the role of hepatic PPARγ expression during mouse liver regeneration. Hepatology 2012;56:1489-98.
34. 2B receptor in chronic liver disease. Nat Med 2011;17:1668-73.
35. Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications. Semin Liver Dis 2015;35:132-45.